Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

34
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
34
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

104
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
104
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

240
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
240
Time Course of Drug Effect01:14

Time Course of Drug Effect

2.0K
The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50...
2.0K
One-Compartment Open Model for IV Bolus Administration: Estimation of Elimination Rate Constant, Half-Life and Volume of Distribution01:09

One-Compartment Open Model for IV Bolus Administration: Estimation of Elimination Rate Constant, Half-Life and Volume of Distribution

227
The one-compartment open model is a simplified approach used in pharmacokinetics to understand the distribution and elimination of a drug administered through an intravenous bolus. This model assumes rapid drug dispersal throughout the body and elimination using a first-order process. Key pharmacokinetic parameters, such as the elimination rate constant (k), half-life (t1/2), and the apparent volume of distribution (Vd), can be estimated from this model. The elimination rate is calculated...
227
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

621
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
621

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Oligonucleotide Ligation Assay (OLA)-Simple: Field Implementation, Usability, and Performance of a near Point-of-Care HIV Drug Resistance Assay in Kenya.

Laboratories·2026
Same author

A Community-Based, Multidisciplinary Training Program to Improve HIV Services for US-Based African Immigrants: Lessons Learned over 5 Years of Implementation.

International journal of environmental research and public health·2026
Same author

The dolutegravir failure cohort: A multi-country longitudinal cohort with a randomised clinical trial of continued dolutegravir versus switch to darunavir in people with viraemia while on dolutegravir in Sub-Saharan Africa (The Ndovu Study) protocol.

PloS one·2026
Same author

HIV Status and COVID-19 Treatment Disparities in the US National Clinical Cohort Collaborative.

Open forum infectious diseases·2026
Same author

Associations between recent intimate partner violence and sustained viral suppression among pregnant and postpartum women living with HIV in western Kenya: A secondary analysis of a prospective cohort (Opt4Mamas).

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics·2025
Same author

Machine learning-optimized perinatal depression screening: Maximum impact, minimal burden.

medRxiv : the preprint server for health sciences·2025

Related Experiment Video

Updated: Jun 14, 2025

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

8.9K

A Physiologically-Based Pharmacokinetic Simulation to Evaluate Approaches to Mitigate Efavirenz-Induced Decrease in

Lilian W Adeojo1, Rena C Patel2, Nancy C Sambol1

  • 1Department of Bioengineering and Therapeutic Sciences, School of Pharmacy, University of California San Francisco, San Francisco, CA 94143-0912, USA.

Pharmaceutics
|August 29, 2024
PubMed
Summary
This summary is machine-generated.

To improve contraceptive efficacy, doubling the levonorgestrel implant dose, especially with efavirenz, may counteract drug interactions. This approach helps maintain effective levonorgestrel levels when co-administered with efavirenz.

Keywords:
PBPK modeldrug interactionefavirenzhormone contraceptivelevonorgestrelpharmacokineticphysiologicplasma protein bindingsimulation

More Related Videos

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

470
Experimental Quantification of Interactions Between Drug Delivery Systems and Cells In Vitro: A Guide for Preclinical Nanomedicine Evaluation
08:47

Experimental Quantification of Interactions Between Drug Delivery Systems and Cells In Vitro: A Guide for Preclinical Nanomedicine Evaluation

Published on: September 28, 2022

1.9K

Related Experiment Videos

Last Updated: Jun 14, 2025

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

8.9K
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

470
Experimental Quantification of Interactions Between Drug Delivery Systems and Cells In Vitro: A Guide for Preclinical Nanomedicine Evaluation
08:47

Experimental Quantification of Interactions Between Drug Delivery Systems and Cells In Vitro: A Guide for Preclinical Nanomedicine Evaluation

Published on: September 28, 2022

1.9K

Area of Science:

  • Pharmacokinetics
  • Drug Interactions
  • Contraception

Background:

  • Levonorgestrel implants are effective contraceptives.
  • Efavirenz, a cytochrome enzyme inducer, can reduce levonorgestrel efficacy.
  • Mitigating this drug interaction is crucial for maintaining contraceptive effectiveness.

Purpose of the Study:

  • To evaluate methods for mitigating the drug interaction between levonorgestrel implants and efavirenz.
  • To assess the impact of altered dosing and other factors on drug concentrations.

Main Methods:

  • Utilized a physiologically-based pharmacokinetic (PBPK) model for levonorgestrel.
  • Simulated higher levonorgestrel doses, lower efavirenz doses, and combined strategies.
  • Investigated effects of changes in plasma protein binding and efavirenz exposure variability.

Main Results:

  • Standard levonorgestrel doses with efavirenz significantly reduced predicted concentrations.
  • Doubling levonorgestrel implant doses increased concentrations to control levels.
  • Decreased protein binding reduced total levonorgestrel; higher efavirenz reduced total and unbound concentrations.

Conclusions:

  • Doubling levonorgestrel implant dosage, particularly with 400 mg efavirenz, may mitigate the interaction.
  • Plasma protein binding and efavirenz metabolism variability may influence clinical outcomes.
  • Further research is needed to validate model predictions with clinical data.